BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 25810010)

  • 21. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
    Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
    Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
    Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
    Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
    Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
    Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma.
    Li F; Shanmugam MK; Chen L; Chatterjee S; Basha J; Kumar AP; Kundu TK; Sethi G
    Cancer Prev Res (Phila); 2013 Aug; 6(8):843-54. PubMed ID: 23803415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
    Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
    Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
    Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
    Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
    Lee JH; Park KS; Alberobello AT; Kallakury B; Weng MT; Wang Y; Giaccone G
    Clin Cancer Res; 2013 Dec; 19(24):6777-86. PubMed ID: 24158701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
    Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
    Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
    Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
    J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
    Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
    Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC.
    Fan TF; Bu LL; Wang WM; Ma SR; Liu JF; Deng WW; Mao L; Yu GT; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(41):43581-93. PubMed ID: 26561201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
    Wang Y; Wang S; Wu Y; Ren Y; Li Z; Yao X; Zhang C; Ye N; Jing C; Dong J; Zhang K; Sun S; Zhao M; Guo W; Qu X; Qiao Y; Chen H; Kong L; Jin R; Wang X; Zhang L; Zhou J; Shen Q; Zhou X
    Mol Cancer Ther; 2017 Apr; 16(4):578-590. PubMed ID: 28138036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma.
    Adachi M; Cui C; Dodge CT; Bhayani MK; Lai SY
    Oral Oncol; 2012 Dec; 48(12):1220-6. PubMed ID: 22770899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.